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AbstrACt
Introduction In Sub-Saharan Africa, the rising rates of 
cerebrovascular and cardiovascular diseases (CBD/CVD) 
are intersecting with an ageing HIV-infected population. 
The widespread use of antiretroviral therapy (ART) may 
confer an additive risk and may not completely suppress 
the risk associated with HIV infection. High-quality 
prospective studies are needed to determine if HIV-
infected patients in Africa are at increased risk of CBD/
CVD and to identify factors associated with this risk. This 
study will test the hypothesis that immune activation 
and dysfunction, driven by HIV and reactivation of latent 
herpesvirus infections, lead to increased CBD/CVD risk 
in Malawian adults aged ≥35 years.
Methods and analysis We will conduct a single-centre, 
36-month, prospective cohort study in 800 HIV-infected 
patients initiating ART and 190 HIV-uninfected controls in 
Blantyre, Malawi. Patients and controls will be recruited from 
government ART clinics and the community, respectively, 
and will be frequency-matched by 5-year age band and 
sex. At baseline and follow-up visits, we will measure 
carotid intima-media thickness and pulse wave velocity 
as surrogate markers of vasculopathy, and will be used to 
estimate CBD/CVD risk. Our primary exposures of interest are 
cytomegalovirus and varicella zoster reactivation, changes in 
HIV plasma viral load, and markers of systemic inflammation 
and endothelial function. Multivariable regression models 
will be developed to assess the study’s primary hypothesis. 
The occurrence of clinical CBD/CVD will be assessed as 
secondary study endpoints.
Ethics and dissemination The University of Malawi 
College of Medicine and Liverpool School of Tropical 
Medicine research ethics committees approved this work. 
Our goal is to understand the pathogenesis of CBD/CVD 
among HIV cohorts on ART, in Sub-Saharan Africa, and 
provide data to inform future interventional clinical trials. 
This study runs between May 2017 and August 2020. 
Results of the main trial will be submitted for publication in 
a peer-reviewed journal.
strengths and limitations of this study
 ► This is one of the first large-scale studies in Sub-
Saharan Africa to explore the relationship between 
HIV infection, latent herpesviruses, inflammation, 
and cardiovascular and cerebrovascular diseases, 
immediately after starting antiretroviral therapy 
(ART).
 ► Clinical events and death will be comprehensively 
reviewed through an endpoint review committee 
using strict diagnostic criteria for events based on 
those used in the INSIGHT (International Network for 
Strategic Initiatives in Global HIV Trials) network or 
validated verbal autopsy for death with limited data.
 ► Because of the recent roll-out of ART in asymptom-
atic patients, there will be an absence of ART-naïve 
population, limiting our ability to explore the impact 
of ART.
 ► Approximately one-third of strokes will be asymp-
tomatic and we anticipate not capturing some of 
these; however, multiple cerebral infarcts without a 
focal neurological deficit will manifest as cognitive 
impairment, which we will screen for and corrob-
orate with MRI in a small number of symptomatic 
cases.
 ► Two-thirds of myocardial infarction will be silent and 
could potentially be missed, and in a nested group 
we will use digital ECG to evaluate this further.
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Figure 1 Hypothetical pathway of the interplay between chronic viruses, immune activation, systemic inflammation, 
endothelial activation and vasculopathy. CIMT, carotid intima-media thickness; IL-6, interleukin-6; PWV, pulse wave velocity; 
VL, Viral Load; HLA-DR, Human Leukocyte Antigen-DR isotype; IFNγ, interferon gamma; TFNα, Tumour Necrosis Factor alpha; 
ICAM-1, intercellular adhesion molecules-1 and hsCRP, high-sensitivity C-reactive protein.
trial registration number ISRCTN42862937.
IntroduCtIon
The growing epidemic of cerebrovascular disease (CBD; 
eg, stroke) and cardiovascular disease (CVD; eg, myocardial 
infarction (MI)) now intersects with the HIV epidemic.1 
Countries such as Malawi have an adult HIV prevalence 
of approximately 10%.2 There is an increased life expec-
tancy among people living with HIV, largely because of 
the successful scale-up of antiretroviral therapy (ART).3 In 
Europe and the USA, HIV is associated with a 50% increased 
risk of CVD compared with HIV-uninfected populations,4 
attributable to long-term ART use and HIV per se.4 5 HIV 
infection is also associated with a 1.8-fold increased risk 
of all-cause heart failure in US veterans.6 Our recent 
case–control study of stroke in Malawian adults is one of 
several examples that demonstrate a high risk of HIV infec-
tion associated with stroke and heart disease, pointing to 
a considerable and unappreciated CBD/CVD risk among 
patients with HIV in this setting.7–10
There are reports of geographical differences in the distri-
bution of CVD risk factors, supporting the argument that 
evidence derived from high-income countries cannot be 
applied to Sub-Saharan (SSA).11 Addressing this knowledge 
gap is essential to the development of clinical drug trials 
for primary prevention of CBD/CVD among individuals 
living with HIV. Vasculopathy due to accelerated atheroscle-
rosis, arterial stiffening and vasculitis are the major mecha-
nisms believed to underlie the CBD/CVD burden.12 13 It is 
hypothesised that despite viral suppression, low-grade HIV 
virus replication and the associated host systemic inflamma-
tion are important drivers of this vasculopathy (figure 1). In 
patients receiving ART, HIV antigenaemia, partly resulting 
from HIV persistence in sanctuary sites, incomplete viro-
logical suppression and virological resurgence, drives the 
chronic immune activation observed in about 20% of 
ART patients in SSA.14 This immune state is characterised 
by ongoing activation and senescence of cell-mediated 
immunity,15 16 increased monocyte/macrophage activa-
tion, stimulation of the interleukin-6 (IL-6) pathway and 
production of acute phase proteins.17–19 Activation of the 
IL-6 pathway is established with atherosclerosis20 21 and may 
also contribute to non-atherosclerotic vasculopathy. Inflam-
mation alone confers a two-fold increased risk of clinical 
CBD/CVD events.22 The current push to introduce more 
effective ART regimens and to start treatment soon after 
HIV diagnosis is made may reduce inflammation and in 
turn CBD/CVD risk.23 However, there is growing evidence 
of chronic inflammation in HIV despite achieving the goal 
of therapy, which is long-term suppression (<50 copies/
mL) of plasma viral load, suggesting adjunctive therapy may 
be required.24–26
In addition to HIV, there is compelling evidence that 
reactivation of latent herpesviruses may be an important 
cause of vasculopathy. In HIV-uninfected elderly popula-
tions from high-income settings, latent cytomegalovirus 
(CMV) infection drives dysregulation of cell-mediated 
immunity,15 27–29 not dissimilar to what is described in 
HIV-associated immune activation.29 CMV and other viral 
proteins have been found in atherosclerotic plaques.20 
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Varicella zoster virus (VZV) can directly infect the vascular 
endothelium to cause vasculitis and subsequent stroke and 
was found to be the most common opportunistic infection 
(prevalence 15%) in a study of HIV-infected patients with 
stroke in Malawi.12 The seroprevalence of herpesviruses is 
high in SSA,30 particularly in HIV-infected populations.16
The involvement of herpesviruses in the mechanistic 
pathway for CBD/CVD is compelling and may offer addi-
tional therapeutic avenues, especially for CMV and VZV. 
However, our understanding is incomplete, and its popula-
tion impact is yet to be defined. It is important to determine 
if, in addition to ART, there is a role for other pharmacolog-
ical interventions targeting latent viral infections or down-
stream inflammatory pathways to reduce vasculopathy in 
HIV-infected patients on ART. Previous work from North 
America supports the potential of treating reactivated 
herpesviruses.31 Furthermore, there are opportunities for 
intervention using the recently licensed letermovir, a treat-
ment for CMV. By focusing on HIV and herpes viral anti-
genaemia and immune dysregulation as mechanisms of 
vasculopathy, this study will identify subgroups of HIV-in-
fected patients on ART at high risk of CBD/CVD, the timing 
of CBD/CVD risk in such patients, as well as potential 
targets for intervention. Utimately, the study goal is to inves-
tigate whether reactivation of herpesviruses and inflamma-
tion are cardiovascular and cerebrovascular risk factors in 
antiretroviral therapy initiators in an African HIV-infected 
population (RHICCA).
study objectives
This study will test the hypothesis that immune activation 
and dysfunction, driven by HIV and reactivation of latent 
CMV/VZV herpesvirus infections, lead to increased 
CBD/CVD risk in adults aged ≥35 years in SSA. We will 
address this through the following objectives:
1. To determine if progression of the surrogate marker of 
CBD/CVD or occurrence of new-onset vasculopathy is 
higher in adults aged ≥35 years with HIV infection on 
ART compared with those without HIV.
2. To determine if progression of surrogate markers of 
CBD/CVD or occurrence of new-onset vasculopathy is 
higher in adults aged ≥35 years with HIV/herpes viral 
antigenaemia or chronic immune activation compared 
with those without HIV/herpes viral antigenaemia or 
chronic immune activation. Specifically, we will deter-
mine if progression of surrogate markers or new-onset 
vasculopathy is higher in the following:
a. In ART patients with reactivated latent herpes viral 
infection, compared with those without reactivated 
latent herpes viral infection.
b. In ART patients with the highest 25% of markers 
for immune activation, inflammation or endothelial 
activation compared with the bottom 25%.
c. In ART patients with incomplete virological sup-
pression or virological resurgence of HIV, compared 
with those with suppressed HIV plasma viral load.
The secondary study objectives are to determine if viral 
antigenaemia or chronic immune activation increases 
the occurrence of the following clinical events: (1) 
stroke, (2) MI, (3) angina (excluding MI), (4) peripheral 
vascular disease (PVD), (5) all-cause death/vascular-re-
lated death and (6) immune reconstitution inflammatory 
vasculopathy.
MEthods And AnAlysIs
study design
To address objective 1, we will conduct a single-centre, 
36-month, prospective cohort study in 800 HIV-infected 
patients initiating ART and 190 HIV-uninfected adults 
aged ≥35 years. HIV-infected and HIV-uninfected partic-
ipants will be frequency-matched by 5-year age band and 
sex. On a 6-monthly basis, we will measure markers of 
viral infection, inflammation and endothelial function 
along with surrogate markers for CBD/CVD (table 1).
study setting
This study will recruit consecutive ART patients from the 
ART clinic of Queen Elizabeth Central Hospital (QECH) 
and ART clinics in several Blantyre City community 
health centres (CHCs). These clinics collectively initiate 
over 100 HIV-infected patients aged ≥35 years onto ART 
each month. HIV-uninfected adults will be selected 
from pre-ART counselling sessions, and from randomly 
selected households in the community by two-stage 
random sampling (of households and individuals within 
households) from a previously enumerated sampling 
frame in the CHC catchment areas.32 All study proce-
dures will be conducted at the QECH, which is located 
adjacent to the Malawi-Liverpool-Wellcome Trust Clinical 
Research Programme (MLW). The QECH also hosts a 
0.35T MRI facility, which will contribute to characterising 
our secondary endpoints.
study participants
Study inclusion criteria will be (1) age ≥35 years and (2) 
resident of Blantyre. HIV-infected patients must further 
be (3) ART-naïve or initiated ART <10 days prior to 
enrolment and (4) initiating standard first-line ART . 
Adult controls must further be (5) HIV-uninfected. Study 
exclusion criteria are (6) clinical history of CBD/CVD, 
(7) pregnancy, (8) critical illness or symptomatic anaemia 
at baseline, and (9) enrolment in an intervention study. 
At the analysis stage abnormal pulse wave velocity (PWV) 
at baseline (as defined in table 2) will be excluded for 
new-onset vasculopathy analysis but not for progression 
of vasculopathy. The same approach will be applied for 
baseline carotid intima-media thickness (CIMT) measure-
ments. If the study participant becomes pregnant after 
recruitment, they will be withdrawn.
Justification of study inclusion and exclusion criteria 
is as follows: in many populations, CBD/CVD risk rises 
sharply from 35 years of age33; thus, individuals aged 35 
and older will be eligible (recruitment of participants 
aged 35–39 will be limited to 15% of the study sample 
to avoid over-representation). Restricting recruitment by 
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Table 1 Laboratory tests and clinical procedures in ART patients and HIV-uninfected adults
Study time points
Baseline 6 months 12 months 18 months
24 
months
30 
months 36 months
Clinical procedures
  PWV X X X X X X X
  CIMT X X
  ABPI X X X X X X X
  Cardiac echo (participant subset) X X
  ECG (participant subset) X X
Cardiometabolic markers
  Creatinine
  Full blood count
X
X
X X
  Cholesterol (LDL, HDL, triglycerides) X X
  Serum glucose/haemoglobin A1c X X
HIV infection and progression
  HIV viral load (patients with HIV) X X X
  CD4 count (patients with HIV) X X X
  HIV rapid test (controls) X X X X
Immune dysregulation
  Soluble markers of systemic 
inflammation
X X X
  Soluble markers of endothelial 
activation
X X X
  CD8 and CD4 T cell activation and 
senescence (participant subset)
X X X X X
  Monocyte/Macrophage activation and 
senescence (participant subset)
X X X X X
Herpesviruses infection
  CMV IgG X X
  VZV IgG X X
ABPI, Ankle Brachial Pressure Index; ART, antiretroviral therapy; CIMT, carotid intima-media thickness; CMV, cytomegalovirus; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; PWV, pulse wave velocity; VZV, varicella zoster virus.
age will enable this study to have greater statistical power. 
For clarity of aetiological inference, the study will assess 
the risk of new-onset vasculopathy not associated with 
pregnancy and thus exclude patients who are pregnant or 
with a history of CBD/CVD. To eliminate confounding by 
ART regimen, patients must initiate on standard first-line 
ART (>90% of ART patients in Blantyre do this). Critically 
ill patients are excluded primarily for ethical reasons.
lAborAtory MEthods
surface immunophenotyping of peripheral blood mononuclear 
cells
Immunophenotyping will be used to characterise 
peripheral blood mononuclear cells (PBMC) isolated 
from blood samples of HIV-uninfected and HIV-in-
fected ART initiators. PBMCs will be harvested by 
density centrifugation using Lymphoprep (Axis Shield, 
UK). PBMCs (2×106) will be stained with anti-CD45 
PerCP CY5.5, anti-CD3 AF700, anti-CD4 BV421, anti-
CD8 PE Dazzle, anti-CD38 BV605, anti-HLA-DR APC 
CY7, anti-CD57 APC, anti-PD1 PE CY7, anti-CTLA4 
PE and anti-CD223 FITC (all from eBioscience, UK) 
to determine the expression of these markers on the 
surface of T cells. In addition, 2×106 PBMCs stained 
with anti-CD16 BV421, anti-CD14 PE, anti-HLA-DR 
PerCP CY5.5, anti-CD45 AF700, anti-CCR2 BV605, 
anti-CD11b APC, anti-CX3CR1 PE Dazzle and anti-
CD38 FITC (all from eBioscience, UK) will be used 
for monocytes. Dead cells, CD3+ T cells and CD56+ 
Natural Killer cells will be excluded using LIVE/DEAD 
Fixable Aqua Dead Cell Stain (Thermo Fisher, UK), 
anti-CD3 BV503 and anti-CD56 BV503 (eBioscience, 
UK), respectively. Stained cells will be acquired on a 
BD LSRFortessa flow cytometer (Becton Dickinson, 
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Table 2 Case definitions of primary and secondary endpoints for the study
Type Definitions
Primary endpoint
Carotid intima-media thickness (CIMT)
The occurrence of new-onset vasculopathy (CIMT, a measure of atherosclerosis): 
CIMT >0.9 mm or >75th percentile of age/sex references values or presence of 
plaque on the carotid scan.
Progression: total change in CIMT at 24 months from baseline.
Pulse wave velocity (PWV)
Occurrence of new-onset vasculopathy (PWV,a measure of arterial stiffness): PWV 
>12 (m/s).
Progression: total change in PWV at 24 months from baseline.
Secondary 
endpoint
Stroke Confirmed (1+2) or 3 or 4 or 5:
1. Acute onset with a clinically compatible course, including unequivocal 
objective findings of a localising neurological deficit.
2. CT or MRI compatible with a diagnosis of stroke and current neurological 
signs and symptoms.
3. Stroke diagnosed as the cause of death at autopsy.
4. Clinical history and positive lumbar puncture compatible with subarachnoid 
haemorrhage.
5. Death certificate or death note from medical record listing stroke as the cause 
of death.
Myocardial infarction (MI Confirmed: one of the following five criteria (adapted from 2007 Universal 
Definition of Myocardial Infarction) (1 + (2 or 3 or 6)) or 4 or 5:
1. Rise and/or fall of cardiac biomarkers (preferably troponin), with at least one 
value above the 99th percentile of the upper reference limit.
2. The occurrence of a compatible clinical syndrome, including symptoms 
consistent with myocardial ischaemia.
3. ECG changes indicative of new ischaemia (new ST changes or new left bundle 
branch block (LBBB)), or development of pathological Q waves on the ECG.
4. Sudden unexpected cardiac death involving cardiac arrest before biomarkers 
are obtained or before a time when biomarkers appear, along with (a) new 
ST changes or new LBBB, or (b) evidence of fresh thrombus on coronary 
angiography or at autopsy.
5. Pathological findings of acute MI (including acute MI demonstrated as the 
cause of death on autopsy).
6. Development of (a) evolving new Q waves or (b) evolving ST elevation, 
preferably based on at least 2 ECGs taken during the same hospital 
admission.
Coronary artery disease requiring drug treatment Confirmed (1 or 2) +3:
1. Evidence of myocardial ischaemia based on either diagnostic imaging (such 
as a stress echocardiogram or thallium scan) or diagnostic changes on an 
ECG (such as during stress testing or an episode of chest pain).
2. Evidence of coronary artery disease based on coronary angiography or other 
diagnostic imaging.
3. Use of medication given to treat or prevent angina (eg, nitrates, beta blockers, 
calcium channel blockers).
Peripheral vascular disease Confirmed (1+2) or (1+3):
1. Compatible clinical signs and symptoms.
2. Positive results on diagnostic imaging studies (eg, Doppler ultrasound, 
contrast arteriography, MRI arteriography).
3. Ankle brachial pressure index <0.90 in non-diabetics.
  Vascular Immune reconstitutionsyndrome (IRIS) A new onset vasculopathy within 6 months of starting ART
  All-cause death and vascular-related deaths Death (of any or vascular cause) that occurs after recruitment into the study.
USA), and data will be analysed using FlowJo V.10.0 
software (Tree Star, San Carlos, California). For each 
stained sample analysed, the median fluorescence 
intensity for each parameter will be normalised to its 
respective unstained control.
Measurement of soluble markers of immune activation using 
multiplex bead array
A custom-made multiplex assay will be used to assess 
soluble markers of monocyte activation (CD163), systemic 
inflammation (IL-6) and endothelial activation (intra-
cellular adhesion molecule 1) in plasma, isolated from 
blood samples of HIV-uninfected and HIV-infected ART 
initiators. Following isolation, plasma will be aliquoted 
and stored at −80°C until further use.
Assessment of exposure to human CMV and VZV by ElIsA
Quantitative VIDAS CMV IgG and IgM (bioMerieux, 
USA) and VZV glycoprotein IgG Low-Level Enzyme 
Immunoassay Kit (VaccZyme EIA) will be used to deter-
mine exposure to these viruses using a commercial 
ELISA platform. These kits will detect VZV antigen to 
a sensitivity and specificity of 97.8% and 96.8% and 
for CMV, 97.2% and 100% for IgG, and 100% and 
97.4% for IgM, respectively.34 35 Plasma samples from 
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Figure 2 Outline of study design for a 36-month cohort study. ART, antiretroviral therapy; cIMT, carotid intima-media 
thickness; PWV, pulse wave velocity; QECH, Queen Elizabeth Central Hospital.
HIV-uninfected and HIV-infected ART initiators stored 
at −80°C following collection will be used for these 
assessments.
human immunodeficiency virus
HIV infection will be diagnosed using two rapid tests in 
parallel (Determine HIV-1/2 (Abbott Laboratories, USA) 
and Uni-Gold HIV (Trinity Biotech, Ireland), and EIA 
rapid tests will be used as a tie-breaker. HIV-1 RNA levels 
in plasma will be measured using the Abbott RealTime 
HIV-1 assay with a lower limit of detection of 150 copies/
mL (Abbott Molecular, Germany), according to the 
manufacturer’s instructions. CD4+ T cell count measure-
ments will be performed using BD FACSCount machine 
(Partec platform).
Procedures
Carotid-femoral PWV36 and CIMT37 measurements will be 
performed in accordance with expert consensus guide-
lines, using a standardised study protocol on the Vicorder 
system (SMART Medical, UK) and Philips CX50 machine 
(Philips Healthcare, UK), respectively. CIMT measure-
ments will be performed by three trained operators. The 
intraclass correlation coefficient will be used to assess the 
performance of the operators against that of a certified 
neurosonologist prior to study commencement.
outCoMEs
Primary outcomes
The primary outcomes are the progression of surrogate 
markers of CBD/CVD, namely PWV and CIMT, as well 
as the occurrence of new-onset vasculopathy defined by 
threshold values outlined in table 2.
secondary outcomes
The secondary outcomes are the following clinical events: 
(1) stroke, (2) MI, (3) unstable angina, (4) PVD, (5) 
all-cause death/vascular death and (6) immune recon-
stitution inflammatory syndrome (IRIS) vasculopathy 
(table 2). Changes in PWV or endothelial activation at 
6 months post-ART initiation will be interpreted as a 
subclinical vascular IRIS event. These outcomes will be 
assessed through active surveillance in QECH inpatient 
wards for admissions of study participants. To improve 
capture of clinical outcomes, we will conduct brief tele-
phone interviews with study participants about CBD/
CVD symptoms and hospitalisations between study visits 
and facilitate unsolicited participant self-report. Clinical 
events and deaths in study participants will be reviewed 
by an independent endpoint review committee (ERC), 
comprising clinicians experienced in endpoint review. 
Each event will be reviewed and adjudicated by the ERC 
chair and two ERC reviewers, using a standard set of diag-
nostic criteria (table 2 and online supplementary S1). 
The format of reporting will be based on modifications of 
the INSIGHT network clinical diagnostic criteria. Deaths 
will be reviewed by the ERC using the International Clas-
sification of Diseases for causes of death classificaton.23 
For death with limited clinical data, a validated verbal 
autopsy will be performed to ascertain the cause.38
Exposures
The exposure for primary objective 1 will be HIV status. 
Yearly HIV rapid tests in HIV-uninfected adults will be 
performed to exclude those with new HIV infections 
(figure 2).
Potential confounding and mediating factors will be 
recorded in study participants. This will include demo-
graphic factors, lifestyle and behavioural factors (eg, 
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cigarette smoking and alcohol consumption), chronic 
comorbidities (ie, hypertension, diabetes), and cardiomet-
abolic, renal and haematological factors (ie, full blood 
count, creatinine in urine and serum, body mass index, 
waist to hip ratio, random glucose, haemoglobin A1c, and 
lipid profile). Blood pressure will be measured at all study 
visits. Although vascular IRIS (table 2) will be considered 
as a primary endpoint, non-vascular IRIS will be defined 
as a risk factor. Where feasible, we will conduct PCR tests 
for common causes of IRIS in blood or cerebrospinal fluid 
samples. Adherence to ART and change of ART regimen 
will be assessed at all study visits through extraction of 
data from ‘ART master cards’; this is a government-sup-
ported monitoring tool used by all patients on ART in 
Malawi.
For objectives 2a–2c, markers of herpes and HIV 
viral antigenaemia and immune inflammation will be 
measured according to the outline in table 1. For primary 
objective 2a, reactivated latent herpes viral infections will 
be assessed by quantification of VZV and CMV antibodies. 
We will estimate the risk of atherosclerosis and arterial 
stiffening associated with current herpesviruses reactiva-
tion at baseline and sustained reactivation (ie, those that 
continue to have a high titre from measurement at base-
line to 6 months after ART initiation). Hyperactivation 
of B cells may result in an expansion of polyclonal anti-
bodies and thus an overestimation of virus-specific anti-
body titres. To address this issue and make appropriate 
adjustments for hypergammaglobulinaemia, we will (1) 
measure more than one herpesviruses and (2) measure 
total IgG.
For primary objective 2b, markers of immune activa-
tion, inflammation and endothelial activation will be 
measured (figure 1 and table 1). Quantitative cell surface 
immunophenotyping will be performed for CD4+ and 
CD8+ T cell activation (eg, Human Leukocyte Antigen – 
DR isotype [HLA-DR]) and senescence (eg, CD57) in a 
subset of participants. In all study participants, at baseline 
and at 6 and 12 months, we will measure soluble markers 
associated with systemic inflammation and endothelial 
activation.
For primary objective 2c, incomplete viral response and 
viral rebound of HIV will be measured by quantitative 
PCR in patients on ART.39 HIV viral load will be measured 
in patients on ART at 0, 6 and 12 months.
data collection between May 2017 and August 2020
The two-stage screening will be conducted to find and 
recruit potential study participants. A trained field-
worker will first screen to assess eligibility for criteria 1–3 
in pre-ART counselling sessions and in individuals from 
randomly selected households in the community. Eligible 
participants will then be referred to the QECH to complete 
screening for criteria 4–9, and if eligible consented to 
participate in the study. At study visits, a tablet-based, 
standardised Open Data Kit case report form will be 
administered in one-on-one interviews by a study nurse to 
capture demographic and clinical data. Study data will be 
collected as outlined in table 1. Daily upload of electronic 
data will occur with oversight from the data manager at 
MLW. We will collect up to 30 mL of whole blood. Urine 
albumin to Creatinine ratio (ACR) dipstick test will be 
used to test for creatinine, proteinuria and glucosuria. In 
a subset of participants, an ECG supported by a digital 
platform and echocardiogram will be performed at base-
line and at 6 and 24 months, as well as in any participant 
experiencing a clinical event suggestive of a cardiac aeti-
ology. To facilitate the retention and clinical referrals 
of participants, contact will be made every 3 months to 
assess the occurrence of clinical events. Participants who 
miss a scheduled study visit will be contacted by phone 
and/or visited at home to assess their willingness to main-
tain their participation and to record intervening clinical 
events. Recording and definitions of other clinical events, 
including HIV-associated events, will be evaluated by the 
ERC chair. SMS (short message service) messages will be 
used for appointment reminders. A technical appendix, 
statistical code and study data sets will be made available 
from a data repository, after publication of our work.
sample size and statistical analysis
The required sample size for the study’s primary objec-
tives is 800 HIV-infected patients and 190 HIV-uninfected 
adults using standard, normal distribution approxima-
tion sample size formulas for comparing proportions in 
two groups of unequal size and based on the following 
assumptions: (1) of HIV-infected study participants, 18.4% 
have abnormal PWV at baseline. We will exclude these 
participants from analysis. The 18.4% figure is informed 
by our ongoing studies of vasculopathy in HIV-infected 
patients, where this is the percentage of participants aged 
≥35 years who have a PWV (>12 m/s). (2) Of both HIV-in-
fected patients and HIV-uninfected adults, 20% will be 
lost to follow-up, including by death and HIV seroconver-
sion.40 41 (3) The minimum relative risk (RR) of interest is 
2 for objective 1 and 1.8 for objective 2. (4) The 24-month 
cumulative risk of clinically significant vasculopathy over 
study follow-up is 18.4% in the HIV-positive group. This is 
based on the same study data cited in (1). (5) For objec-
tives 2a–2c, the exposure prevalence for each risk factor 
is 20%. (6) Statistical tests will have 80% power based on 
a two-sided test with α=0.05. Testing of hypotheses for 
the secondary outcome will be exploratory. However, we 
estimate 26 strokes (4 mimics), an unknown number of 
MIs and 80 deaths occurring during the study.7 42 Taken 
together, assumptions (3), (4) and (5) mean that, for 
80% power, we assume a 24-month cumulative vascu-
lopathy risk of 9.2% in HIV-negative participants, 18.4% 
in all HIV-infected participants, 15.9% in HIV-infected 
participants not exposed to the risk factors from objec-
tives 2a–2c and 28.6% in the HIV-infected participants 
exposed to these risk factors.
The reporting of this study will be prepared in accor-
dance with the Strengthening the Reporting of Obser-
vational Studies in Epidemiology guidelines.43 Summary 
and descriptive statistics will be tabulated for all primary 
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and secondary outcome variables, as well as for exposure 
variables and potential confounding or mediating factors. 
Time plots for all outcome variables will be inspected. 
Quantitative data analysis will be conducted to assess the 
primary outcomes.
There will be three analysis time points: (1) after recruit-
ment has finished and baseline data are available for all 
participants (baseline analysis); (2) once every partici-
pant has completed 6 months in the study (6-month anal-
ysis); and (3) at 36 months, when each participant has 
completed 24 months in the study (final analysis).
The baseline analysis will largely consist of descriptive 
statistics on participant characteristics and data recorded 
at baseline. Simple regression models will also be used to 
investigate relationships between exposure and outcome 
variables measured at baseline. Unadjusted analyses will 
consist of paired t-tests or Wilcoxon signed-rank tests 
(depending on whether the data are normally distributed 
or not) for continuously measured variables, and χ2 or 
Fisher’s exact tests (depending on contingency table cell 
counts) for binary and categorical variables. Adjusted 
analyses will be conducted using generalised linear 
models (GLMs).
The 6-month analysis will be limited in scope and serves 
two purposes: (1) characterise new-onset vasculopathy in 
HIV-infected participants who have initiated ART treat-
ment at baseline (vascular IRIS) and (2) define vasculop-
athy outcomes for the final analysis. The main analysis of 
the study data will be conducted at the final analysis time 
point.
For objective 1 we will develop three regression models. 
Two GLMs will be developed to compare mean progres-
sion of arterial damage from baseline in HIV-infected 
ART patients and HIV-uninfected adults. These models 
will regress change from baseline PWV and CIMT, respec-
tively, on HIV status. We will develop a third model to 
estimate the RR and population-attributable fraction 
of new-onset arterial damage in HIV-infected patients 
compared with HIV-uninfected adults.
For objective 2a, a set of GLMs will be developed to 
compare mean progression of vasculopathy in HIV-infected 
ART patients with and without reactivated latent herpes 
viral infection. These models will regress PWV and CIMT, 
respectively, on, on two log-transformed variables for anti-
body titres of CMV and VZV.
For objective 2b, we will again fit a set of GLMs, with 
change from baseline in PWV as response variable, this 
time to investigate if, in HIV-infected ART patients, there 
is an association between progression of vasculopathy and 
immune activation and inflammation biomarkers (IL-6, 
Intracellular adehesion molecule [ICAM], CD163). Specifi-
cally, for each marker, we will regress PWV on marker quan-
tiles. After having built models for each marker, we will 
then develop comprehensive multiple regression models 
for PWV and CIMT with multiple independent markers as 
predictor variables.
For objective 2c, we will proceed as for objective 2a, but 
comparing HIV-infected ART patients with incomplete 
virological suppression or virological resurgence of HIV 
with those with suppressed HIV plasma viral load.
In addition to these analyses, given the repeated 
measurements for PWV, immune activation and inflam-
mation markers, we will extend the GLMs for PWV to 
linear mixed models taking full account of the longitu-
dinal nature of the data. Mixed models will also handle 
deviations from the visit schedule in a principled fashion 
and use all available data for dropouts. If a log link func-
tion is required for PWV in the GLMs, we will fit margin-
alised models using Generlaised Estimating Equations 
[GEE] instead of Linear Mixed Models [LMMs].
For the secondary study objectives, we will use univariate 
methods to assess the frequency of clinical events within 
exposure strata. If there are sufficient numbers of clinical 
events, we will develop Poisson or negative binomial regres-
sion models (depending on model fit) for each clinical 
event type to compare exposure-defined participants.
We will also use time-to-event models, specifically Cox 
proportional hazard models, to investigate associations 
between all-cause mortality and exposures.
As part of exploratory analyses, we will aim to identify 
risk groups that are potentially incompletely captured 
with the measured exposure variables. We will perform 
unsupervised group-based multitrajectory modelling of 
multivariate longitudinal patient trajectories to confirm 
any associations we have found using more traditional 
approaches.44
All efforts will be made to collect complete data on 
all study participants. However, there will inevitably 
be missing data due to dropouts and a variety of other 
reasons. All primary analyses will be performed using 
multiple imputation. For sensitivity analyses, we will use 
all available cases, direct likelihood and fully Bayesian 
models, and for GEE models weighted GEE. If the 
number of missingness patterns is sufficiently small, we 
will also use pattern mixture models which can be used 
under the general missing-not-at-random setting but 
make additional identification assumptions.
PAtIEnt PublIC InVolVEMEnt
The global burden of HIV-associated CBD and CVD has 
tripled over the last two decades with the greatest impact 
in SSA. CBD and CVD are a priority for patients in Malawi 
as HIV infection is endemic and the population are living 
for longer. Knowledge of this informed our research 
question with the aim of understanding the mechanisms 
and thus direct targeted novel therapies to reduce this 
burden. Patients will be involved in the recruitment of 
the study, but not in the design. Patients and their advi-
sors will be thanked for contributing to the study.
EthICs And dIssEMInAtIon
Written informed consent will be obtained from all 
study participants, either written or witnessed verbal 
consent with thumbprint if the participant is non-literate. 
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Study data will be maintained in an encrypted and pass-
word-protected database to which only study staff will 
have access. Study participants who develop a clinical 
event will be managed, using the hospital guidelines, by 
our study clinician alongside the hospital doctor. Clinical 
data will be anonymised using unique identifying code. 
Study data will be kept for 10 years and then destroyed 
with a record, as recommended by good clinical prac-
tice guidelines. Results of the main trial and each of the 
secondary endpoints will be submitted for publication in 
a peer-reviewed journal.
dIsCussIon
African regions continue to bear the brunt of HIV 
infection. In 2013, an estimated 8.5 million adults were 
receiving ART.45 As the landscape evolves, this popula-
tion will live longer with stable HIV infection but likely 
remain at an increased risk of CBD/CVD compared with 
HIV-uninfected individuals of similar age and sex. This 
study will be the first to determine the extent to which 
HIV reactivation of herpesvirus infection and inflam-
mation contribute to CBD/CVD risk in an adult African 
population starting ART. The results of this work could 
potentially open avenues for novel anti-inflammatory 
and antiviral interventions for the primary prevention of 
CBD/CVD in HIV populations in Africa.
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